The AlphaLISA® immunoassay kit for human BTLA enables the quantitative determination of human B- and T-lymphocyte attenuator (BTLA, CD272) in serum, buffered solution, and cell culture media using a homogeneous AlphaLISA assay (no wash steps).
You successfully added item(s) to your cart
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
B- and T-lymphocyte attenuator (BTLA), also known as CD272, is a 35 kDa transmembrane protein that is expressed on Th1 cells, B cells and NK cells. BTLA's main function is to regulate T cell activation by acting as an inhibitor when interacting with HVEM, B7-H4 and TNF receptors. Deletion of BTLA results in the overproduction of T cells, especially CD8+ cancer specific memory T cells. Higher expression of BTLA is correlated to patients with lung cancer and sepsis. This kit is designed to detect and quantify the levels of BTLA in cell culture supernatant and serum.
|Assay Target Class||Protein|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 Assay Points|
Protocol for performing an AlphaLISA human BTLA detection and quantitation assay